WIDEX MOMENT™ Hearing Aids Named CES 2021 Innovation Awards Honoree: Earns Recognition In Health & Wellness and Wearable Technologies Categories

Widex Inc. today announced that it has been named a CES® 2021 Innovation Awards Honoree for the company’s WIDEX MOMENT™ natural-sounding hearing aids. The announcement comes ahead of the first-ever, all-digital CES 2021, happening Jan. 11-14, 2021.

WIDEX MOMENT was selected as an honoree in the CES 2021 Innovation Awards Health & Wellness and Wearable Technologies categories for its groundbreaking solution, which is the first digital hearing aid to incorporate dual artificial intelligence engines to improve real-time listening. Furthermore, the WIDEX MOMENT leverages ZeroDelay technology to reduce the standard sound delay from 7-10 milliseconds seconds to 0.5 milliseconds, creating natural sound that transforms how people with hearing loss experience the world.

“Widex engineers have worked tirelessly over five years to create a unique, natural hearing platform like WIDEX MOMENT,” said Søren Hvidberg Nielsen, President of Widex US. “Hearing aids aren’t only used to amplify speech. For people who benefit from them, they open a far wider aural window onto the lives they want to experience. We are grateful the CES Innovation Awards judges recognized the incredible potential of WIDEX MOMENT as a wearable and wellness device.”

The WIDEX MOMENT utilizes artificial intelligence to create a better sound experience that leads to higher user acceptance. The device’s SoundSense Learn technology adjusts hearing aid settings in two ways using artificial intelligence. First, WIDEX MOMENT learns how users prefer to hear their surroundings by analyzing settings and guiding them through a series of A-B comparisons. Second, they draw from millions of user settings stored in the cloud to help personalize the listening experience.

WIDEX MOMENT hearing aids also include Widex PureSound™ ZeroDelay™ technology, a groundbreaking parallel processing path that all but eliminates latency, resulting in a more natural sound without the “tinny” distortions associated with other hearing aids. By reducing processing latency to just 0.5 milliseconds, Widex ZeroDelay provides users with a new level of clear, natural sound that wasn’t possible in older devices.

The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)®, is an annual competition honoring outstanding design and engineering in consumer technology products across 28 product categories. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”